MCDC

The Access to Advanced Health Institute (AAHI) announced today that it has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate based on AAHI’s self-amplifying RNA (saRNA) platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

In the two Phase 2 trials, PUL-042 was evaluated in one trial as preemptive treatment in patients with early, symptomatic infection and in a second trial in the prophylactic settings in subjects with known exposure to SARS-CoV-2. The Phase 2 studies of PUL-042 for COVID-19 are funded in part with federal funds from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), through the U.S. Army Contracting Command - New Jersey, under an Other Transaction Agreement (W15QKN-16-9-1002, Project #MCDC 2006-002) awarded to the Medical CBRN Defense Consortium and Pulmotect, Inc.

Pulmotect, Inc., a clinical-stage biotechnology company, announced positive topline results from the first of two Phase-2 clinical trials undertaken with the support of the US Department of Defense (DOD) to evaluate PUL-042 against COVID-19. The Phase 2 studies of PUL-042 for COVID-19 are funded in part with federal funds from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical), through the U.S. Army Contracting Command - New Jersey, under an Other Transaction Agreement (W15QKN-16-9-1002, Project #MCDC 2006-002) awarded to the Medical CBRN Defense Consortium and Pulmotect, Inc.

Through the new contract, awarded through the Medical CBRN Defense Consortium, Leidos plans to use a new clinical trial prototype, which uses an electronic data capture system to collect, evaluate and assess symptom severity.

Pulmotect, Inc., a clinical-stage biotechnology company, has received funding from the Department of Defense (DOD) to complete two ongoing COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042.